Page last updated: 2024-09-03

lestaurtinib and Pancreatic Neoplasms

lestaurtinib has been researched along with Pancreatic Neoplasms in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	2 (66.67)	18.2507
2000's	1 (33.33)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Berlin, J; Chan, E; Holen, KD; Lockhart, AC; Mulkerin, D; Rothenberg, M; Thomas, J	1
Dionne, CA; Klein-Szanto, AJ; Miknyoczki, SJ; Ruggeri, BA	1
Chang, H; Dionne, CA; Klein-Szanto, A; Miknyoczki, SJ; Ruggeri, BA	1

Trials

1 trial(s) available for lestaurtinib and Pancreatic Neoplasms

Article	Year
A phase I trial of CEP-701 + gemcitabine in patients with advanced adenocarcinoma of the pancreas. Investigational new drugs, 2008, Volume: 26, Issue:3 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carbazoles; Deoxycytidine; Drug Administration Schedule; Drug Interactions; Female; Furans; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Pancreatic Neoplasms	2008

Article

Year

A phase I trial of CEP-701 + gemcitabine in patients with advanced adenocarcinoma of the pancreas.

Investigational new drugs, 2008, Volume: 26, Issue:3

Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carbazoles; Deoxycytidine; Drug Administration Schedule; Drug Interactions; Female; Furans; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Pancreatic Neoplasms

2008

Other Studies

2 other study(ies) available for lestaurtinib and Pancreatic Neoplasms

Article	Year
The novel Trk receptor tyrosine kinase inhibitor CEP-701 (KT-5555) exhibits antitumor efficacy against human pancreatic carcinoma (Panc1) xenograft growth and in vivo invasiveness. Annals of the New York Academy of Sciences, 1999, Jun-30, Volume: 880 Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Carbazoles; Enzyme Inhibitors; Female; Furans; Humans; Indoles; Injections, Subcutaneous; Mice; Mice, Inbred BALB C; Mice, Nude; Molecular Structure; Neoplasm Invasiveness; Neoplasm Transplantation; Pancreatic Neoplasms; Rats; Receptor Protein-Tyrosine Kinases; Trachea	1999
The Trk tyrosine kinase inhibitor CEP-701 (KT-5555) exhibits significant antitumor efficacy in preclinical xenograft models of human pancreatic ductal adenocarcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research, 1999, Volume: 5, Issue:8 Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Body Weight; Carbazoles; Drug Screening Assays, Antitumor; Female; Furans; Humans; Immunohistochemistry; Indoles; Mice; Mice, Nude; Neoplasm Invasiveness; Neoplasm Transplantation; Pancreatic Neoplasms; Rats; Receptor, trkA; Time Factors; Trachea; Treatment Outcome; Tumor Cells, Cultured	1999

Article

Year

The novel Trk receptor tyrosine kinase inhibitor CEP-701 (KT-5555) exhibits antitumor efficacy against human pancreatic carcinoma (Panc1) xenograft growth and in vivo invasiveness.

Annals of the New York Academy of Sciences, 1999, Jun-30, Volume: 880

Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Carbazoles; Enzyme Inhibitors; Female; Furans; Humans; Indoles; Injections, Subcutaneous; Mice; Mice, Inbred BALB C; Mice, Nude; Molecular Structure; Neoplasm Invasiveness; Neoplasm Transplantation; Pancreatic Neoplasms; Rats; Receptor Protein-Tyrosine Kinases; Trachea

1999

The Trk tyrosine kinase inhibitor CEP-701 (KT-5555) exhibits significant antitumor efficacy in preclinical xenograft models of human pancreatic ductal adenocarcinoma.

Clinical cancer research : an official journal of the American Association for Cancer Research, 1999, Volume: 5, Issue:8

Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Body Weight; Carbazoles; Drug Screening Assays, Antitumor; Female; Furans; Humans; Immunohistochemistry; Indoles; Mice; Mice, Nude; Neoplasm Invasiveness; Neoplasm Transplantation; Pancreatic Neoplasms; Rats; Receptor, trkA; Time Factors; Trachea; Treatment Outcome; Tumor Cells, Cultured

1999